Muutke küpsiste eelistusi

Business Ethics in the Healthcare Industry [Kõva köide]

Edited by , Edited by
  • Formaat: Hardback, 751 pages, kõrgus x laius: 235x155 mm, 21 Illustrations, color; 6 Illustrations, black and white
  • Ilmumisaeg: 03-Jan-2026
  • Kirjastus: Springer Nature Switzerland AG
  • ISBN-10: 303207648X
  • ISBN-13: 9783032076489
  • Kõva köide
  • Hind: 187,84 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 220,99 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 3-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Hardback, 751 pages, kõrgus x laius: 235x155 mm, 21 Illustrations, color; 6 Illustrations, black and white
  • Ilmumisaeg: 03-Jan-2026
  • Kirjastus: Springer Nature Switzerland AG
  • ISBN-10: 303207648X
  • ISBN-13: 9783032076489
Newscasts and social networks denounce fraud and professional dishonesty in the healthcare domain quite frequently, even though a few of these are groundless fake news and even scams. This book aims a scientific approach to all forms of fraud, misconduct, and breach of ethics in the healthcare business. Chapters will be written by respected professors worldwide, emphasizing not sensation and impact but a reasoned and scholarly description of the problems, roots, impacts and solutions.



A systematic analysis of each ecosystem and the most prevalent forms of misconduct and unethical procedures will be provided. This encompasses drug manufacturers, health insurance and health maintenance organizations, including telehealth and internet healthcare providers, analytical testing services for clinical services and consumer health purposes, including genomics and other omics sequencing, producers and distributors of surgical material, imaging apparatuses and general hospital equipment, personal electronic health monitoring devices, and robotic developers for assistance to small children, the handicapped, the elderly and other medically relevant populations. The emphasis will be descriptive and constructive, about the roots of the issue and involved environments, agents and stakeholders, and concerning what can and should be done to curb the prevalence and consequences of abuses. Medical, scientific, and ethical authorities will be most of the contributors; however, social professionals, lawyers, and economists will help from different vantage points to enrich the messages.



Students, trainees, and professionals are the target, primarily in medicine, pharmacy, nursing, and nutrition, along with business administrators, accountants, and lawyers. All areas of the healthcare business are envisaged, encompassing the related fields of law, social sciences, and the rapidly growing ethics/bioethics field. Policy makers and government agencies should not be overlooked.
1. Health equity, diversity and inclusion: Critical foundations for
ethical leadership.-
2. Should doctors work with the pharmaceutical industry
?.-
3. Industry influence on healthcare provider behaviors.-
4. Promoting
world health with equity: From patents to impact funds.-
5. Nursing homes and
end of life care: An ethical paradigm ?.-
6. Thick concepts and
pharmaceutical industry corruption.-
7. Fake drugs, real concerns.-
8. Ethics
of off label marketing of drugs: Patient safety versus commercial profits.-
9. Small pharma ethical behavior.-
10. Informational quarantine: Should it be
punishable to spread medical disinformation during a pandemic ?.-
11.
Industry payments.-
12. Global implementation of tobacco demand reduction
measures specified in framework convention on tobacco control .-
13.
Understanding the problems of medical student  exposure to pharmaceutical
marketing.-
14. Ten challenges to healthcare business ethics in the XXI
century.-
15. Ethics and sustainability in food production and consumption.
The vegan paradigm .-
16. Bribery in Japan´s medical device sector.-
17. Risk
of recall among medical devices undergoing US FDA 510(k) clearance and
premarket approval.-
18. Implant ethics between business and the clinic.-
19.
Xenotransplation.-
20. Internet links to illegal pharmacies.-
21. Illicit
online pharmacies.-
22. Dietary supplements adulterated with drugs and
contaminated with heavy metals.-
23. Experimental therapies with the
application of the EU Hospital  Exemption Regulation for Advanced Therapy
Medicinal Products European and Polish perspectives.-
24. Ethics in dental
services: business as usual ?.-
25. Advertisement techniques and biologic
treatment in psoriasis.-
26. Keeping medical science trustworthy: the threat
by predatory journals.-
27. The ethics of  internet healthcare crowdfunding.-
28. The complex dynamics of decision-making at the end of life in the
intensive care unit.-
29. Medical Board transparency regarding physician
sexual misconduct.-
30. Abusive supervision, nursing workforce, and patient
safery outcomes.-
31. Dignity in end-of-life care in hospice.-
32. Ethical
issues in clinical decision-making about involuntary psychiatric treatment.-
33. Conflicts of interest in biomedical, social and environmental aspects of
health.-
34. Ethics of sustainability in healthcare.-
35. Energy conservation
and sustainability in the clinical laboratory.-
36. Private equity and its
increasing role in the US.-
37. Racism and healthcare in Germany.-
38. Access
to healthcare by migrants.-
39. Sexual and reproductive health care for
migrant women.-
40. Addressing Socioeconomic Disparities in Healthcare
Outcomes of Children  in the United States of America.-
41. Ethical
Challenges in Mental Healthcare for South Asian, Particularly Sikh, Survivors
of Domestic Abuse .-
42. Inclusive Diversity Management in Healthcare: The
Ethics of Including the Voices and Experiences of Asian Professionals in
Healthcare.-
43. Barriers in healthcare for transgender individuals.-
44.
Ethics for artificial intelligence in medicine.-
45. Tribulations and Future
Opportunities for Artificial Intelligence in Precision Medicine  March 2025.-
46. Business Ethics and the Declaration of Helsinki.-
47. Ethics advancement
and internet sites.
Joel Faintuch MD is a gastrointestinal surgeon, and former International Guest Fellow of the American College of Surgeons. He is Honorary Fellow of three foreign Surgical Societies and has served as Visiting Professor at the University of Maastricht. During his career, he has been interested in a variety of subjects, including nutrition, metabolism, obesity, and ethics in research. He was the introducer of Parenteral and Enteral Nutrition in Brazil and South America and a founding member of different medical societies. In the last 20 years, he has acted as vice-president of the Ethics in Research Committee, Hospital das Clinicas and Sao Paulo University Medical School, which is the oldest and largest in Latin America. Dr. Faintuch is the author of over 270 articles in peer-reviewed journals, along with 12 books, three theses, over 200 chapters in books, and other publications.

Salomao Faintuch MD is a radiologist and Clinical Director of Vascular and Interventional Radiology at Beth Israel Deaconess Medical Center, Harvard Medical School. He has authored more than 50 articles in peer-reviewed journals, along with 8 Society Guidelines and Standards of Practice. He is a Radiological Society of North America Research Scholar, has participated in eight National Society Committees and is a member of the Editorial Board of three international journals.